• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » InnFocus closes $33.9M Series C financing

InnFocus closes $33.9M Series C financing

December 22, 2015
CenterWatch Staff

InnFocus has closed its Series C financing, which raised additional monies to total $33.9 million.

The Miami-based company is developing the InnFocus MicroShunt (IMS) glaucoma drainage system to treat early, moderate and late-stage primary open angle glaucoma (POAG). The final phase of its FDA clinical trials will begin next month.

The InnFocus MicroShunt FDA clinical trial is the only company sponsored prospective randomized study that compares a device to the trabeculectomy procedure, which has been the “gold standard” for treating glaucoma for about 50 years. Patients with mild, moderate and severe glaucoma are included in the study.

Completion of phase I included more than 100 cases performed in the U.S. More than 250 patients have now been treated with the InnFocus MicroShunt device in Canada, France, Japan, the Netherlands, Spain, Switzerland, the Dominican Republic and the U.S.

The company has reported prospective results on mild, moderate, and severe glaucoma patients treated outside the U.S. with up to three years of follow up. Patients have experienced a mean reduction in intraocular pressure (IOP) from about 24 mm Hg on full medication to below 15 mm Hg, with more than 70% of patients completely off glaucoma medication three years after their surgery. Pressures below 15 mm Hg reduce a major risk factor for optic nerve damage and subsequent vision loss, which can occur when IOP is too high.

The InnFocus MicroShunt was developed in collaboration with the University of Miami’s Miller School of Medicine, Bascom Palmer Eye Institute. It provides a quick minimally invasive procedure for shunting aqueous humour from the anterior chamber to the same “gold standard” drainage path used in trabeculectomy. The device is made from SIBS, an innovative highly biocompatible material that has been implanted in the body for more than 15 years.

The InnFocus MicroShunt was designed to shunt aqueous humor without the need to cut scleral tissue, control suture tension, or utilize patch grafts. It has been implanted alone or in combination with cataract surgery in prospective studies outside the U.S.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing